Key terms

About ARVN

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest ARVN news

Today 2:40am ET Analysts’ Top Healthcare Picks: Quanterix (QTRX), Intuitive Surgical (ISRG) by TipRanks Yesterday 6:47am ET Arvinas price target lowered to $87 from $90 at H.C. Wainwright by TipRanks Apr 12 8:29am ET Piper Sandler Sticks to Their Buy Rating for Arvinas Holding Company (ARVN) by TipRanks Apr 12 7:10am ET Analysts Offer Insights on Healthcare Companies: Prime Medicine, Inc. (PRME), Arvinas Holding Company (ARVN) and Viridian Therapeutics (VRDN) by TipRanks Apr 11 1:05pm ET Buy Rating Affirmed for Arvinas Amid Strategic Novartis Deal and Growth Potential by TipRanks Apr 11 7:05am ET Arvinas enters exclusive strategic license agreement with Novartis for ARV-766 by TipRanks Apr 03 7:10am ET Wall Street Analysts Are Bullish on Top Healthcare Picks by TipRanks Mar 18 5:04pm ET Arvinas Appoints New Chief Medical Officer for Clinical Programs by TipRanks Mar 18 4:46pm ET Arvinas names Noah Berkowitz as Chief Medical Officer by TipRanks Mar 01 12:58am ET Arvinas Holding Company: A Buy Rating on Strong Clinical Pipeline and Promising Trial Outcomes by TipRanks Feb 29 5:52am ET Arvinas price target raised to $60 from $26 at Barclays by TipRanks Feb 28 8:46am ET Arvinas price target raised to $59 from $33 at Wedbush by TipRanks Feb 28 7:36am ET Arvinas Holding Company: Buy Rating Backed by Promising Breast Cancer Therapy and Strategic Expansion into Parkinson’s Disease Treatment by TipRanks Feb 28 7:30am ET Piper Sandler Keeps Their Buy Rating on Arvinas Holding Company (ARVN) by TipRanks Feb 28 5:40am ET Buy Rating Affirmed for Arvinas Holding Company Amid Strong Drug Candidate Prospects and Robust Financial Health by TipRanks Feb 27 4:23pm ET Arvinas VERITAC-2 trial timelines not changed, says Oppenheimer by TipRanks Feb 27 3:46pm ET Arvinas Holding Company: A Strong Buy on Robust Clinical Data and Strategic Trial Advancements by TipRanks Feb 27 7:02am ET Arvinas expects cash to fund operations into 2027 by TipRanks Feb 27 7:01am ET Arvinas reports Q4 EPS ($2.53), consensus ($1.27) by TipRanks Feb 20 4:27pm ET Arvinas CFO Sean Cassidy to Resign, Interim Successor Named by TipRanks Feb 20 4:26pm ET Arvinas announces resignation of CFO Sean Cassidy by TipRanks Feb 20 7:12am ET Arvinas announces first-in-human dosing of ARV-102 by TipRanks Feb 14 8:22am ET Carrick announces first patient dosed in trial of samuraciclib, vepdegestrant by TipRanks Feb 14 7:35am ET Arvinas downgraded to Neutral from Buy at Citi by TipRanks Feb 08 5:46am ET Arvinas Holding Company: A Promising Buy Amidst Progressive Drug Development and Strategic Collaborations by TipRanks Feb 08 5:26am ET Goldman Sachs Predicts at Least 45% Rally for These 2 ‘Strong Buy’ Stocks — Here’s Why They Have Solid Upside by TipRanks Feb 06 6:49am ET Arvinas, Pfizer: FDA grants Fast Track designation for ARV-471 by TipRanks Feb 01 11:49pm ET 3 Best Stocks to Buy Now, 2/2/2024, According to Top Analysts by TipRanks Feb 01 9:58am ET Qualcomm downgraded, Cigna upgraded: Wall Street’s top analyst calls by TipRanks Feb 01 4:44am ET Arvinas initiated with a Buy at Goldman Sachs by TipRanks Feb 01 2:25am ET Goldman Sachs Initiates Buy Rating on Arvinas with a Focus on Innovative Cancer Treatments and Strategic Growth Potential by TipRanks

No recent news articles are available for ARVN

No recent press releases are available for ARVN

ARVN Financials

1-year income & revenue

Key terms

ARVN Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

ARVN Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

Tim Wren, chief commercial officer for BSI Group, right, presents Kristalina Georgieva, chief executive officer of the World Bank Group, second right, with ISO 20121 certification for sustainable event management at an event during the spring meetings of the International Monetary Fund (IMF) and World Bank in Washington, DC, US, on Monday, April 15, 2024. The IMF and World Bank spring meetings in Washington are expected to draw thousands of delegates, observers and journalists from the fund's 190 member countries. Photographer: Samuel Corum/Bloomberg via Getty Images
Samuel Corum/Bloomberg/Getty Images
Geopolitical strife is roiling Wall Street. Here’s what investors are watching
Donald Trump might no longer own a majority of TMTG after a new public share offering.
Joe Raedle/Getty Images
Trump stock tanks after announcing massive share sale
1040 US Individual Income Tax Return Form
Nora Carol Photography/Moment RF/Getty Images
Three ways investors can minimize their tax payments
People walk past the New York Stock Exchange (NYSE) on April 10, 2024 in New York City.
Spencer Platt/Getty Images
Dow closes nearly 500 points lower on fears of potential Iranian attack on Israel